Melatonin has become the supplement American parents reach for most when their young children cannot sleep. A systematic review published in JAMA Network Open now quantifies how far ahead of the evidence that trend has moved — and the findings are sobering.
The review, conducted by researchers at the University of Kansas Medical Center, analyzed 19 studies spanning 2000 to 2025, including 12 observational studies and 6 experimental trials. The central conclusion: melatonin use in children aged zero to six has increased dramatically, prescribing periods have lengthened, adverse event reports have risen, and the long-term safety data that would justify these trends are largely absent.
The Scale of the Problem
The numbers behind the surge are stark. Data from the National Poison Data System show that pediatric melatonin ingestions reported to poison control centers increased 530% over a 10-year period from 2012 to 2021, with 260,435 total incidents involving children. Pediatric hospitalizations and serious outcomes also increased, primarily driven by unintentional ingestions among children aged five and under.
Melatonin is now the leading cause of unsupervised medication exposure and overdose-related emergency department visits in young children — surpassing other over-the-counter medications that are subject to child-resistant packaging requirements.
Why the Gap Matters
The review found that among good- and fair-quality studies, melatonin improved sleep onset in children with neurologic conditions such as autism spectrum disorder and ADHD. However, in children with typical development, the evidence for benefit was inconsistent.
More concerning is what the studies did not examine. Data on long-term outcomes — including effects on hormonal development, pubertal timing, and behavior — were "generally absent" across the reviewed literature. Most trials lasted only weeks to months, yet the review found that in practice, melatonin use frequently begins in toddlerhood and continues for approximately 12 months or longer, suggesting parents use it as a nightly sleep aid rather than a short-term chronobiotic intervention.
Experts have raised particular concern about the potential for exogenous melatonin to affect hormonal development in very young children, whose endogenous melatonin systems are still maturing.
A Regulatory Vacuum
Unlike prescription medications, melatonin is sold as a dietary supplement in the United States and is not subject to FDA approval, standardized dosing, or rigorous manufacturing oversight. Independent testing has found that many melatonin products contain significantly more or less melatonin than labeled — and some contain contaminants including serotonin.
The gummy formulations that dominate the children's market compound the risk. Young children cannot distinguish melatonin gummies from candy, which is a primary driver of the unintentional ingestion spike. Unlike acetaminophen or ibuprofen, melatonin products are not required to use child-resistant closures.
This regulatory gap places the entire burden of safe use on parents, many of whom reasonably assume that a product marketed for children and available without a prescription has been vetted for pediatric safety.
What Pediatricians Recommend
The American Academy of Pediatrics advises against melatonin use in children under five. For older children, recommendations include:
- Start with behavioral interventions first — consistent bedtime routines, limited screen time before bed, and a cool, dark sleeping environment address the most common causes of pediatric sleep difficulty
- Use the lowest effective dose if melatonin is necessary, typically 0.5 to 1 mg for children aged five and older
- Limit the duration of use and reassess regularly with a pediatrician
- Store melatonin out of reach and avoid gummy formulations when possible
- Consult a physician before starting melatonin, particularly in children with existing medical conditions
The Broader Context
The melatonin surge in young children reflects a broader pattern in which supplement use has outpaced clinical evidence. A March 2026 ScienceDaily report highlighted growing alarm among pediatricians, noting that the number of children taking melatonin at least monthly has risen nearly 20-fold since 2018.
The JAMA review's authors emphasized an "urgent need to carefully evaluate the safety, effectiveness, and appropriate use of melatonin in pediatric care" and called for stronger oversight of melatonin products, including clearer labeling standards and child-resistant packaging requirements.
What This Means for Patients
Parents currently giving melatonin to young children should not panic but should reassess. A conversation with a pediatrician can help determine whether melatonin is genuinely indicated or whether behavioral sleep strategies might address the underlying issue.
For parents whose children do benefit from melatonin under medical supervision, the key practical steps are to verify the product's quality through third-party testing databases, use the lowest effective dose, and store the product with the same caution applied to any medication.
The gap between melatonin's perceived safety and its actual evidence base is not a reason to ban the supplement — it is a reason to close the gap with the research and regulatory attention that a product used by millions of children deserves.
